Ibuprofen
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
- Ibuprofen
- Ibuprofen: From Analgesic/Anti-inflammatory to Acromesomelic Dysplasia, Hunter-Thompson Type
Using the txgnn-pipeline skill to guide this report generation. Now producing the evaluation report based on the Evidence Pack.
Ibuprofen: From Analgesic/Anti-inflammatory to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Ibuprofen is a well-established non-steroidal anti-inflammatory drug (NSAID), widely used for pain relief, fever reduction, and inflammatory conditions such as arthritis. The TxGNN model predicts it may be effective for Acromesomelic Dysplasia, Hunter-Thompson Type — a rare autosomal recessive skeletal dysplasia caused by GDF5/CDMP1 loss-of-function mutations — with 0 clinical trials and 0 publications currently supporting this direction. This prediction rests entirely on graph network topology and carries no supporting clinical or preclinical evidence at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from CBG-MEB registry (no NL authorizations found in dataset) |
| Predicted New Indication | Acromesomelic Dysplasia, Hunter-Thompson Type |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 |
| NL Market Status | Not registered (no CBG-MEB RVG authorizations found) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data was not available in this evidence pack. Based on established pharmacological knowledge, Ibuprofen is a prototypical NSAID that inhibits both COX-1 and COX-2 cyclooxygenase enzymes, thereby suppressing prostaglandin synthesis. This results in analgesic, antipyretic, and anti-inflammatory effects. Its well-known clinical applications include musculoskeletal pain, dysmenorrhoea, fever, and inflammatory arthropathies.
Acromesomelic dysplasia, Hunter-Thompson type is an extremely rare congenital skeletal dysplasia caused by loss-of-function mutations in the GDF5 gene (also known as CDMP1). GDF5 is a bone morphogenetic protein (BMP) family member that plays a critical role in chondrocyte differentiation and long bone development. The theoretical mechanistic link is that PGE2 — a downstream COX-2 product — modulates BMP signalling in chondrocytes. In principle, COX-2 inhibition by Ibuprofen could alter PGE2-mediated BMP pathway activity in cartilage.
However, the mechanistic link is assessed as extremely weak and directionally uncertain. Suppressing COX-2/PGE2 could simultaneously reduce local inflammation and interfere with residual GDF5-dependent bone development signalling — opposing effects that make the net clinical outcome unpredictable. This is a congenital structural disorder caused by a genetic defect; it is not an acquired inflammatory condition. The high TxGNN score most likely reflects graph-topological proximity to other musculoskeletal diseases in which Ibuprofen has established activity, rather than a true mechanism-based repurposing opportunity. All 7 TxGNN-predicted indications for Ibuprofen in this dataset share this same pattern: rare skeletal or developmental dysplasias with L5 evidence and Hold recommendations.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Netherlands Market Information
No CBG-MEB RVG authorizations were found for Ibuprofen in the current dataset.
Important note: This likely reflects a data collection gap in the regulatory pipeline rather than actual NL market absence. Ibuprofen is a widely authorised OTC and prescription medicine throughout the EU. Please verify current authorization and RVG status directly via the CBG-MEB public register or the EMA product database before drawing any conclusions about NL market availability.
Safety Considerations
Please refer to the SmPC (Summary of Product Characteristics) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN prediction score (99.74%), acromesomelic dysplasia, Hunter-Thompson type is a congenital skeletal dysplasia caused by a specific genetic defect in the GDF5/BMP pathway. The mechanistic connection to Ibuprofen’s COX-2 inhibition mechanism is speculative, directionally ambiguous, and entirely unsupported by any clinical trial, observational data, or published literature (L5 — model prediction only). Proceeding without foundational evidence would not meet CBG-MEB or EMA repurposing standards.
To proceed, the following is needed:
- Regulatory data verification: Retrieve actual CBG-MEB RVG authorization records and SmPC for Ibuprofen to establish the NL regulatory baseline
- MOA data from DrugBank: Query DrugBank API (DB01050) to obtain the full mechanism of action and target interaction profile to formally assess the COX-2 / GDF5-BMP pathway hypothesis
- Safety data: Obtain complete SmPC warnings, contraindications, and drug-drug interaction data before any further evaluation stage
- Preclinical evidence: Commission or identify cell-based or animal studies examining COX-2 inhibition in GDF5-deficient skeletal models; without this, biological plausibility cannot be established
- Expert consultation: Engage skeletal dysplasia specialists and a clinical pharmacologist to assess whether anti-inflammatory intervention could have any disease-modifying role in this congenital condition
- Reassessment of all 7 predictions: All TxGNN-predicted indications for this drug are rare skeletal/developmental dysplasias at L5 with no supporting evidence — a systematic review of the full prediction set is recommended to identify whether any higher-priority repurposing signal exists across Ibuprofen’s broader disease network
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.